Can a lower drug dose prevent transplant complications just as well?
NCT ID NCT06705062
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after stem cell transplants from unrelated or half-matched donors. About 316 participants will receive either a reduced dose (35 mg/kg) or the standard dose (50 mg/kg), along with other immune-suppressing drugs. The goal is to see if the lower dose works as well but causes fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclophosphamide (reduced dose 35 mg/kg vs standard 50 mg/kg), tacrolimus, and anti-thymocyte globulin
What this could lead to
If successful, this could offer a safer way to prevent graft-versus-host disease after stem cell transplants, with fewer side effects and similar protection.
What could go wrong
This is a phase 3 trial, but the reduced dose may not prevent GVHD as well as the standard dose. Results may not apply to all transplant types or patient groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Ruijin hsopital
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact